Last reviewed · How we verify
NCT06731439
Does Starting Feeds on the First Day of Life Help Premature Infants Reach Full Volume Feeds Sooner?
NA trial testing Starting feeds within 6 hours of life in Extra Uterine Growth Restriction in 248 participants. Currently enrolling.
30 June 2026
Quick facts
| Lead sponsor | University of Tennessee |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | prevention |
| Enrollment | 248 |
| Start date | 1 June 2024 |
| Primary completion | 30 June 2026 |
| Estimated completion | 30 June 2027 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Starting feeds within 6 hours of life
- Standard feeding protocol
Conditions studied
- Extra Uterine Growth Restriction — all drugs for Extra Uterine Growth Restriction →
- Premature Infant Disease — all drugs for Premature Infant Disease →
- VLBW - Very Low Birth Weight Infant — all drugs for VLBW - Very Low Birth Weight Infant →
Sponsor
University of Tennessee
Who can join
Adults 1 Minute to 6 Hours, any sex, with Extra Uterine Growth Restriction or Premature Infant Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Feeding advancements in ELBW infants have evolved over decades. The fear of causing mortality and morbidity, notably NEC, have made providers cautious when advancing feeds. ELBW infants initially remained NPO for several days before initiating trophic feeds. However, data then showed that there was no increase in mortality and morbidity if trophic feeds were initiated earlier. Then data showed that a short duration of trophic feeds did not increase mortality and morbidity when compared to a prolonged duration. More recent data showed that enteral feeding should be initiated early, preferably within 24 hours of birth, because it may promote feeding tolerance, shorten the time to reach total enteral feeding, and reduce the incidence of extrauterine growth restriction and late onset sepsis without increasing the risk of developing NEC. The management of enteral nutrition in ELBW infants is still very variable. For example, there is no consensus on the optimal time point after birth at which enteral nutrition can be started. This study evaluates the benefits of starting feeds by 6 hours of life Purpose: The primary aim of this study is to evaluate if in infants ≤ 1000g birth weight, is there a benefit initiating feeds by 6 hours of life (compared to current feeding practice data of 3 days of life) on decreasing the time to attain full feeds in the first 30 days of life. The secondary aim is to evaluate if antenatal feeding discussions would streamline feeding management post-delivery.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06731439
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other University of Tennessee trials
Trials by the same sponsor.
- NCT07465432 — Pharmacokinetic Analysis of Cefiderocol in Patients With Acute Burn Injuries · Phase 4 · recruiting
- NCT07225725 — Access to Care Pilot for ED-Presenting Head and Neck Cancer Patients (ENRICH-HNC) · NA · not yet recruiting
- NCT07227519 — Effects of UPF Warning Labels on Social Media Among Teens and Young Adults · NA · not yet recruiting
- NCT06850857 — Multi-Institutional IMPACT Validation · enrolling by invitation
- NCT06745180 — Making Healthy Habits Stick · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06731439 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Tennessee
- Last refreshed: 12 December 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06731439.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing